| Line Item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 |
|---|---|---|---|---|---|---|---|---|---|
| Research and development expenses, net | — | ||||||||
| General and administrative expenses | |||||||||
| Impairment of fixed assets | — | ||||||||
| Operating income (loss) | |||||||||
| Other income (expense): | |||||||||
| Impairment of loans receivable | — | ||||||||
| Income on Debt Extinguishment and Conversion | |||||||||
| Finance income, net | |||||||||
| Net income (loss) | |||||||||
| Net income (loss) per ordinary share - basic (in Dollars per share) | |||||||||
| Net income (loss) per ordinary share - diluted (in Dollars per share) |